Key result
Statin adherence rapidly declines in ~19% of older adults on concurrent triple therapy.
Why the study?
Prior studies focused on adherence to statin monotherapy or composite adherence to triple therapy, leaving limited evidence on statin-specific adherence patterns among older adults receiving concurrent triple therapy.
What are the statin adherence trajectories and their predictors among older adults on concurrent triple therapy?
Cohort (n=7,847)
What are the statin adherence trajectories and their predictors among older adults on concurrent triple therapy?
Among older adults on triple therapy for dyslipidemia, hypertension, and diabetes, nearly 20% experience a rapid decline in statin adherence, with female sex and prior hospitalization being key predictors.
May warrant closer adherence monitoring in women and younger adults on triple therapy; hypothesis-generating for targeted interventions.
Aim: Older adults with dyslipidemia often have coexisting diabetes and hypertension, requiring triple therapy with statins, antihypertensives, and oral antidiabetics. Given that statin adherence is a key metric in the Medicare STAR Ratings program, understanding statin use in this population is critical. However, prior studies have focused on adherence to statin monotherapy or composite adherence to triple therapy, with limited evidence on statin-specific patterns in this population. Methods: We conducted a retrospective cohort study using a Texas-based Medicare Advantage database (2016–2017). Adults receiving concurrent triple therapy (statins, renin-angiotensin system antagonists, and oral antidiabetics) were followed for 12 months. Statin adherence was measured monthly using the proportion of days covered (PDC) and modeled using group-based trajectory modeling (GBTM). Multinomial logistic regression, informed by the Andersen behavioral model, was used to identify sociodemographic and clinical predictors of adherence trajectories. Results: Among 7,847 patients, three distinct statin adherence trajectories were identified: near-perfect adherence (57.0%), adherent (23.6%), and rapid decline (19.4%). Female sex was associated with higher odds of rapid decline than male sex. Younger age (≤ 65 years) and having at least one prior hospitalization were significant predictors of rapid adherence decline, whereas older age and a greater number of concomitant medications were associated with lower odds of decline. Notably, about 80% of patients were adherent to statin despite lower adherence to the overall triple-therapy regimen. Conclusions: This study identified three distinct statin adherence trajectories among older adults on triple therapy. By highlighting predictors of rapid adherence decline, including female sex and prior hospitalization, these findings can help clinicians identify high-risk patients and inform targeted interventions to improve adherence and cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Ofili et al. (2026) conducted a cohort in Dyslipidemia with coexisting diabetes and hypertension (n=7,847). Concurrent triple therapy (statins, RAS antagonists, oral antidiabetics) was evaluated on Rapid decline statin adherence trajectory. Among older adults on concurrent triple therapy, three distinct statin adherence trajectories were identified over 12 months: near-perfect adherence (57.0%), adherent (23.6%), and rapid decline (19.4%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: